Emiliano Calvo, MD, PhD

Calvo, Emiliano 2019 120x160

Dr. Calvo is the Director of Clinical Research at START Madrid, and works as a Medical Oncologist clinical investigator at Centro Integral Oncológico Clara Campal hospital, in Madrid, Spain. He is also the President of the non-profit organization Investigational Therapeutics in Oncological Sciences Foundation (Intheos). In addition, he is an Associate Professor in Oncology and Director of the Oncology PhD/Doctorate Program at Universidad CEU San Pablo.
Dr. Calvo is a member of the ESMO Faculty Group Principles of Clinical Trials and Systemic Therapy. He has been a member of the Scientific Committee of the ESMO annual meeting, member of the Scientific Committee of the Targeted Agents Therapies (TAT) and also at the annual EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, where he has been appointed as co-Chair of the Scientific Committee from 2019 on.
He is also co-Director of the ECCO-AACR-EORTC-ESMO International Workshop in Methods in Clinical Cancer Research -MCCR Workshop, Zeist, Netherlands-. Also, Dr. Calvo was Track Leader (2015-6) and Committee member (2013-6) for the Scientific Program Committee on the Developmental Therapeutics - Clinical Pharmacology & Experimental Track of the Annual Meetings of the American Society of Clinical Oncology (ASCO), as well as honorary member of the Cancer Education Committee of ASCO (2015-2016).
Dr. Calvo has co-authored approximately one hundred publications on clinical development of new drugs in different tumor types. He serves as an ad-hoc reviewer of various oncology journals and has been appointed board editor for European Journal of Cancer and Investigational New Drugs, and is a consultant for different national cancer programs (Italy, UK, France). During the last 15 years of almost full dedication to Clinical Drug development in Oncology, he has participated in around two hundred international studies, as a clinical investigator, especially in Early Clinical Drug Development, and, during the last decade, especially focused on immunotherapy.